[{"orgOrder":0,"company":"Pharmavite","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"S-Equol","moa":"Estrogen receptor beta; Sex hormone-binding globulin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmavite \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Bonafide Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmavite \/ Pharmavite","highestDevelopmentStatusID":"15","companyTruncated":"Pharmavite \/ Pharmavite"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bonafide-HF3.0","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonafide Health \/ Lindus Health","highestDevelopmentStatusID":"1","companyTruncated":"Bonafide Health \/ Lindus Health"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"JDS-HF","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonafide Health \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Bonafide Health \/ Nutrasource"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Triglyceride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Pharmavite","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Pharmavite","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Pharmavite"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmavite \/ Undisclosed"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials Ltd."}]

Find Clinical Drug Pipeline Developments & Deals by Pharmavite

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Sleep.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 20, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dysbiosis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 24, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Bonafide-HF3.0 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 04, 2024

                          Lead Product(s) : Bonafide-HF3.0

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Lindus Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.

                          Product Name : Relizen

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 30, 2023

                          Lead Product(s) : Bonafide Pollen

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Bonafide Health

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Triglyceride is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Triglyceride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : JDS-HF is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hot Flashes.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          April 14, 2023

                          Lead Product(s) : JDS-HF

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Nutrasource

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Study Phase : Undisclosed

                          Recipient : Midwest Center for Metabolic and Cardiovascular Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 12, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Midwest Center for Metabolic and Cardiovascular Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : S-equol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 18, 2020

                          Lead Product(s) : S-Equol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Biofortis Mérieux Nutriscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 26, 2019

                          Lead Product(s) : Melatonin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : KGK Science

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Eicosapentaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 22, 2018

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Midwest Center for Metabolic and Cardiovascular Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank